MXPA03000405A - Uso de 2 alfa-metil-19-nor-20(s)-1alfa,25-dihdroxivitamina d3 para incrementar la resistencia de los huesos. - Google Patents

Uso de 2 alfa-metil-19-nor-20(s)-1alfa,25-dihdroxivitamina d3 para incrementar la resistencia de los huesos.

Info

Publication number
MXPA03000405A
MXPA03000405A MXPA03000405A MXPA03000405A MXPA03000405A MX PA03000405 A MXPA03000405 A MX PA03000405A MX PA03000405 A MXPA03000405 A MX PA03000405A MX PA03000405 A MXPA03000405 A MX PA03000405A MX PA03000405 A MXPA03000405 A MX PA03000405A
Authority
MX
Mexico
Prior art keywords
bone
2agr
1agr
dihydroxyvitamin
activity
Prior art date
Application number
MXPA03000405A
Other languages
English (en)
Spanish (es)
Inventor
Hector F Deluca
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of MXPA03000405A publication Critical patent/MXPA03000405A/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22D—CASTING OF METALS; CASTING OF OTHER SUBSTANCES BY THE SAME PROCESSES OR DEVICES
    • B22D17/00—Pressure die casting or injection die casting, i.e. casting in which the metal is forced into a mould under high pressure
    • B22D17/20—Accessories: Details
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22D—CASTING OF METALS; CASTING OF OTHER SUBSTANCES BY THE SAME PROCESSES OR DEVICES
    • B22D17/00—Pressure die casting or injection die casting, i.e. casting in which the metal is forced into a mould under high pressure
    • B22D17/20—Accessories: Details
    • B22D17/22—Dies; Die plates; Die supports; Cooling equipment for dies; Accessories for loosening and ejecting castings from dies
    • B22D17/2236—Equipment for loosening or ejecting castings from dies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22D—CASTING OF METALS; CASTING OF OTHER SUBSTANCES BY THE SAME PROCESSES OR DEVICES
    • B22D17/00—Pressure die casting or injection die casting, i.e. casting in which the metal is forced into a mould under high pressure
    • B22D17/20—Accessories: Details
    • B22D17/22—Dies; Die plates; Die supports; Cooling equipment for dies; Accessories for loosening and ejecting castings from dies
    • B22D17/24—Accessories for locating and holding cores or inserts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MXPA03000405A 2000-07-14 2001-07-10 Uso de 2 alfa-metil-19-nor-20(s)-1alfa,25-dihdroxivitamina d3 para incrementar la resistencia de los huesos. MXPA03000405A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/616,778 US6306844B1 (en) 1997-03-17 2000-07-14 Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
PCT/US2001/021660 WO2002005824A1 (en) 2000-07-14 2001-07-10 USE OF 2α-METHYL-19-NOR-20(S)-1α,25-DIHYDROXYVITAMIN D3 TO INCREASE BONE STRENGTH

Publications (1)

Publication Number Publication Date
MXPA03000405A true MXPA03000405A (es) 2003-06-06

Family

ID=24470903

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03000405A MXPA03000405A (es) 2000-07-14 2001-07-10 Uso de 2 alfa-metil-19-nor-20(s)-1alfa,25-dihdroxivitamina d3 para incrementar la resistencia de los huesos.

Country Status (16)

Country Link
US (4) US6306844B1 (cg-RX-API-DMAC7.html)
EP (1) EP1305030B1 (cg-RX-API-DMAC7.html)
JP (1) JP4955895B2 (cg-RX-API-DMAC7.html)
KR (1) KR100572958B1 (cg-RX-API-DMAC7.html)
CN (1) CN1250225C (cg-RX-API-DMAC7.html)
AT (1) ATE359796T1 (cg-RX-API-DMAC7.html)
AU (2) AU7330301A (cg-RX-API-DMAC7.html)
BR (1) BR0112453A (cg-RX-API-DMAC7.html)
CA (1) CA2416187A1 (cg-RX-API-DMAC7.html)
DE (1) DE60127964T2 (cg-RX-API-DMAC7.html)
DK (1) DK1305030T3 (cg-RX-API-DMAC7.html)
ES (1) ES2286129T3 (cg-RX-API-DMAC7.html)
IL (2) IL153908A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03000405A (cg-RX-API-DMAC7.html)
NZ (1) NZ524018A (cg-RX-API-DMAC7.html)
WO (1) WO2002005824A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
AU2001278888B2 (en) * 2000-07-14 2005-04-07 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(s)-1alpha,25-dihydroxyvitamin D3 to increase bone strength
US7858602B2 (en) * 2000-10-16 2010-12-28 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells
US20030195175A1 (en) * 2002-03-25 2003-10-16 Deluca Hector F. Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone
DE60310050T2 (de) 2002-03-29 2007-07-05 Wisconsin Alumni Research Foundation, Madison Ein verfahren zur herstellung von 1-alpha-hydroxy-2-methylen-19-nor-homopregnacalciferol
US6846811B2 (en) * 2002-04-22 2005-01-25 Wisconsin Alumni Research Foundation (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses
RU2317992C2 (ru) 2003-02-25 2008-02-27 Кей Эн Си Лэборэтериз Ко., Лтд. Новые промежуточные соединения для синтеза производных витамина d
CA2539361A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
NZ555278A (en) * 2004-11-22 2010-12-24 Wisconsin Alumni Res Found 17,20(e)-dehydro vitamin D analogs and their uses
US20100144671A1 (en) * 2005-03-04 2010-06-10 Women And Infants Hospital Of Ri, Inc. Compositions and Methods for Cancer Treatment
US7241909B2 (en) * 2005-05-03 2007-07-10 Wisconsin Alumni Research Foundation 19,26,27-trinor-1α,25-dihydroxyvitamin D3 compounds
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
US7803789B2 (en) * 2006-02-02 2010-09-28 Wisconsin Alumni Research Foundation Vitamin D analog—RAK, methods and uses thereof
AU2007234717B2 (en) * 2006-04-06 2012-04-19 Wisconsin Alumni Research Foundation 2-methylene-1alpha,25-dihydroxy-19,21-dinorvitamin D3 analogs and uses thereof
MX2008012114A (es) * 2006-04-06 2009-03-06 Wisconsin Alumni Res Found Analogos 19-nor-vitamina d con anillo 1,2, o 3,2 heterociclico.
AU2007298673A1 (en) 2006-04-06 2008-03-27 Wisconsin Alumni Research Foundation 2- substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin D analogs and uses thereof
AU2007349772A1 (en) * 2006-04-06 2008-10-23 Wisconsin Alumni Research Foundation 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin D3 and uses thereof
EP2001841B1 (en) * 2006-04-06 2012-06-13 Wisconsin Alumni Research Foundation 2-methylene-1 alpha-hydroxy-18,19,21-trinorvitamin d3 analogs and uses thereof
WO2008035207A2 (en) * 2006-04-06 2008-03-27 Wisconsin Alumni Research Foundation 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof
MX2008012674A (es) * 2006-04-10 2008-10-15 Wisconsin Alumni Res Found Compuestos de 1 a-hidroxi-2-(3'-hidroxipropiliden)-19-nor-vitamina d con una cadena lateral 1,1-dimetilpropilo.
EP2020989A2 (en) * 2006-05-15 2009-02-11 Wisconsin Allumni Research Foundation Pulmonary delivery of 1,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin
US7893043B2 (en) * 2008-07-10 2011-02-22 Wisconsin Alumni Research Foundation 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs
US8222236B2 (en) * 2008-07-10 2012-07-17 Wisconsin Alumni Research Foundation 2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs
US7888339B2 (en) * 2008-07-10 2011-02-15 Wisconsin Alumni Research Foundation 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs
WO2011017165A1 (en) * 2009-08-03 2011-02-10 Wisconsin Alumni Research Foundation Method of preventing renal disease and treating symptoms thereof
CA2777938C (en) * 2009-10-21 2017-11-14 Wisconsin Alumni Research Foundation Method of preventing type 1 diabetes
ES2545403T3 (es) * 2010-03-23 2015-09-10 Wisconsin Alumni Research Foundation (20S)-2-metilen-19-nor-22-dimetil-1alfa,25-dihidroxivitamina D3 y (20R)-2-metilen-19-nor-22-dimetil-1alfa,25-hidroxivitamina D3
WO2011119622A1 (en) * 2010-03-23 2011-09-29 Wisconsin Alumni Research Foundation DIASTEREOMERS OF 2-METHYLENE-19-NOR-22-METHYL-1α,25- DIHYDROXYVITAMIN D3
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
US20130295083A1 (en) * 2012-05-02 2013-11-07 Wisconsin Alumni Research Foundation 2a-Methyl-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2AMD) or 2 methylene-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2MD) Support Survival and Function of Transplanted Islet Cells In Type 1 Diabetes
RU2666995C2 (ru) 2012-06-29 2018-09-13 Висконсин Алюмни Рисерч Фаундейшн ПРИМЕНЕНИЕ 2-МЕТИЛЕН-19-НОР-(20S)-1α,25-ДИГИДРОКСИВИТАМИНА D3 ДЛЯ ЛЕЧЕНИЯ ВТОРИЧНОГО ГИПЕРПАРАТИРЕОЗА
US9539264B2 (en) 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
WO2017184262A1 (en) * 2016-04-18 2017-10-26 Wisconsin Alumni Research Foundation Use of 2amd and 2md to treat fibrosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0078704B1 (en) 1981-11-02 1987-04-29 Research Institute For Medicine And Chemistry Inc. Intermediates in the synthesis of vitamin d derivatives
US4666634A (en) 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
GB8904154D0 (en) 1989-02-23 1989-04-05 Leo Pharm Prod Ltd Chemical compounds
NZ232734A (en) 1989-03-09 1991-11-26 Wisconsin Alumni Res Found 19-nor vitamin d derivatives and pharmaceutical compositions
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
AU649057B2 (en) 1990-08-24 1994-05-12 Wisconsin Alumni Research Foundation Methods and compositions containing vitamin D compounds for improvement of skin conditions
DK0474517T3 (da) 1990-09-07 1999-08-02 Wisconsin Alumni Res Found Hidtil ukendt anvendelse af 1alfa-hydroxyleret-19-nor-vitamin D-
US5086191A (en) 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
AU650751B2 (en) 1991-05-28 1994-06-30 Wisconsin Alumni Research Foundation Novel synthesis of 19-nor vitamin D compounds
DE69400495T2 (de) 1993-04-05 1997-04-30 Wisconsin Alumni Res Found 19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle
WO1996001811A1 (en) 1994-07-11 1996-01-25 The Johns-Hopkins University 2-substituted 1,25-dihydroxyvitamin d3 derivatives
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6316642B1 (en) * 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US5962707A (en) * 1998-08-18 1999-10-05 Wisconsin Alumni Research Foundation 19-nor-vitamin D3 compounds with calcemic activity

Also Published As

Publication number Publication date
EP1305030A1 (en) 2003-05-02
JP4955895B2 (ja) 2012-06-20
ATE359796T1 (de) 2007-05-15
CA2416187A1 (en) 2002-01-24
US20060003973A1 (en) 2006-01-05
BR0112453A (pt) 2003-08-19
EP1305030B1 (en) 2007-04-18
AU7330301A (en) 2002-01-30
CN1501803A (zh) 2004-06-02
DE60127964D1 (de) 2007-05-31
DK1305030T3 (da) 2007-09-17
IL153908A0 (en) 2003-07-31
IL153908A (en) 2009-08-03
JP2004509853A (ja) 2004-04-02
HK1066487A1 (en) 2005-03-24
AU2001273303B8 (en) 2006-03-09
AU2001273303B2 (en) 2006-02-02
US20040072804A1 (en) 2004-04-15
US20020151528A1 (en) 2002-10-17
KR20030016402A (ko) 2003-02-26
NZ524018A (en) 2006-06-30
US6306844B1 (en) 2001-10-23
WO2002005824A1 (en) 2002-01-24
US6939868B2 (en) 2005-09-06
KR100572958B1 (ko) 2006-04-24
DE60127964T2 (de) 2008-01-17
CN1250225C (zh) 2006-04-12
ES2286129T3 (es) 2007-12-01

Similar Documents

Publication Publication Date Title
MXPA03000405A (es) Uso de 2 alfa-metil-19-nor-20(s)-1alfa,25-dihdroxivitamina d3 para incrementar la resistencia de los huesos.
MXPA03000406A (es) Uso de 2-metilen-19-nor-20(s)-1 alfa,25-dihidroxivitamina d3 para incrementar la resistencia de los huesos.
IL164688A0 (en) Pharmaceutical compositions containing 1?-hydroxy-2-methyl-19-nor-vitamin D3 compounds
MY146504A (en) 2-propylidene-19-nor-vitamin d compounds
Van Lieshout et al. Bone graft substitutes and bone morphogenetic proteins for osteoporotic fractures: what is the evidence?
BR9808010B1 (pt) Compostos de 2-alquil-19-nor-vitamina d e composição farmacêutica compreendendo os mesmos
MXPA02009590A (es) Compuestos de 2-alquiliden-19-norvitamina d y sus usos terapeuticos.
BR0308355A (pt) Composto ou um sal farmaceuticamente aceitável ou um seu enanciÈmero, métodos para modular uma função mediada pelo receptor de androgênio em um mamìfero em necessidade de tal modulação, para ativar a função do receptor de androgênio em um mamìfero em necessidade de tal ativação, para tratar uma condição em um mamìfero, e para tratar osteoporose em um mamìfero em sua necessidade, composição farmacêutica, métodos para aumentar a densidade mineral óssea em um mamìfero em necessidade disto, para reduzir o risco de fraturas vertebrais ou não vertebrais em um mamìfero em necessidade disto, e para produzir um marcador de modificação óssea em um mamìfero em necessidade disto, processo para produzir uma composição farmacêutica, e, método para tratar ou prevenir uma condição artrìtica em um mamìfero em necessidade disto
ATE537834T1 (de) 2-methylen-19-nor-vitamin d2-verbindungen
NZ547930A (en) Set of osteosynthesis plates
AR010873A1 (es) Compuestos antagonistas del receptor de vitronectina, intermediarios, metodos de su preparacion, composiciones farmaceuticas, uso de dichoscompuestos para la fabricacion de medicamentos.
ATE534623T1 (de) 2-alkyliden-18,19-dinor-vitamin-d-verbindungen
NZ535843A (en) Use of carbon-2-modified-19-nor-vitamin D analogs to induce the formation of new bone
MX9800801A (es) Proteina mp52 arg humana.
In et al. Cruciate-retaining stemmed total knee arthroplasty for supracondylar-intercondylar femoral fractures in elderly patients: a report of three cases
CN201350104Y (zh) 髌骨改良锁定钢板
ATE350043T1 (de) 2-methylen-19-nor-20(s)-25-methyl-1alpha- hydroxycalciferol und seine verwendungen
DE60236411D1 (de) Verwendung von g-csf als zusätzliche behandlung in die wiederherstellung von bindegewebe
Iyer The Adult Hip and Its Disorders
Herath et al. External Fixation
UA36327A (uk) Пристрій для остеосинтезу багатоосколкових переломів передньої частини п'яткової кістки з фрагментацією задньої суглобової фасетки
UY26651A1 (es) Terapia combinada para la osteoporosis
UA31563A (uk) Спосіб вправлення переломів шийки стегна
UA28851A (uk) Спосіб оперативного лікування переломів дистального метаепіфізу великогомілкової кістки

Legal Events

Date Code Title Description
FG Grant or registration